Orforglipron GLP-1 36mg Capsules

Orforglipron is an investigational, once-daily oral glucagon-like peptide-1 GLP-1 receptor agonist. It is being studied for the treatment of type 2 diabetes and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Orforglipron : Here’s a summary of key information about orforglipron: Mechanism: Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. It mimics the natural hormone GLP-1, activating GLP-1 receptors in the gut and brain. This helps regulate blood sugar, delay gastric emptying, reduce appetite, and promote feelings of fullness. Distinction: Unlike other GLP-1 receptor agonists that are peptide-based and typically injected like Ozempic or Wegovy, orforglipron is a small-molecule drug that can be taken orally as a once-daily pill. It does not require food or water restrictions for administration. Clinical trial results: Weight Management : In Phase 2 studies, Orforglipron led to significant weight loss, ranging from 9.4percent to 14.7percent at 36 weeks. In the ACHIEVE-1 trial, participants on the highest dose lost an average of 16.0 lbs 7.9percent. Side effects: The most common side effects are mild to moderate gastrointestinal events, including diarrhea, nausea, dyspepsia, constipation, and vomiting. These were reported to be consistent with the safety profile of other GLP-1 receptor agonists.